ClinicalTrials.gg
Status unknownNCT05070962StuCoTraUpdated Oct 7, 2021

Complex Post-traumatic Stress Disorder: What Symptomatological Specificities

An observational study in Psychiatric Health, sponsored by Raincy Montfermeil Hospital Group. Status unknown at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-07.

Primary conditionnone(registry's first term: Disease)No conditionIs this wrong?Disease describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Raincy Montfermeil Hospital Group · Observational

How we know

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A better understanding of the Complex Post-Traumatic Stress Disorder would allow a management as close as possible to the specificities of this one, but also a better training of professionals and adapted therapeutic indications.

Read the detailed description

Post-Traumatic Stress Disorder manifests itself in a multitude of symptoms and self-regulation difficulties in various domains (somatization and biological balance, attention and consciousness, regulation of affects and impulses, interpersonal relationships and relational capacities, perception of the aggressor and of the aggression, self-perception and identity, sense and belief system) as well as profound changes in personality and various comorbidities .In addition, dissociation, the origin and the resulting disorders also have some similarities to Complex Post-Traumatic Stress Disorder. Indeed, dissociation is thought to have a traumatic origin and the symptomatology (eg hyperesthesia, dissociative amnesia, anesthesia) is included in Complex Post-Traumatic Stress Disorder. We can then ask ourselves the following questions: is Complex Post-Traumatic Stress Disorder a dissociative disorder in its own right causing difficulties with self-regulation? What is the share of dissociation in Complex Post-Traumatic Stress Disorder?

02

Conditions studied

  • Psychiatric Health

Browse trials for

Keywords

  • Disorder,
  • complex post-traumatic stress disorder
  • personality disorders
03

In context

Lead sponsor

Raincy Montfermeil Hospital Group is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The clinical population is made up of individuals who are victims of repeated trauma and are cared for in specialized centers; The general reference population is made up of volunteer students from the University of Lille.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For clinical population;

  • Age between 18 and 65 years old;
  • Having experienced repeated and prolonged traumatic exposure;
  • Able to understand and answer self-questionnaires;
  • Having expressed their free and
  • Affiliated with a social security scheme

For general population:

  • Student volunteers from the University of Lille;
  • Aged between 18 and 65 years old;
  • Able to understand and answer self-questionnaires;
  • Having expressed their free and informed consent.

Exclusion criteria

Exclusion Criteria:

For clinical population;

  • People with difficulties in answering the self-questionnaires (e.g. incomprehension of items, emotional difficulties);
  • Persons under tutorship or curatorship;
  • Persons deprived of their liberty.

For general population:

  • People with difficulties in answering the self-questionnaires (e.g. incomprehension of items, emotional difficulties);
  • Persons under tutorship or curatorship;
  • Persons deprived of their liberty;
  • Persons having a link of subordination with the investigative team.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Clinical population

    having experienced repeated and prolonged traumatic exposure

    Other: clinical population

  • General population

    Student volunteers from the University of Lille

    Other: clinical population

Interventions

  • Otherclinical population

    or the general population, students of the University of Lille will be offered the opportunity to participate in a study through posters in the corridors of the faculties and announcements in the lecture halls.

    Also known as: general poupulation

06

What researchers measure

Primary outcomes

  1. the symptomatological characteristics of Complex Post-Traumatic Stress Disorder

    to evaluate the symptomatic characteristics of TSPTc evoked by the authors (cognitions, emotional regulation, comorbidities, etc.) in order to better identify the symptomatic specificities of the disorder and improve its management.

    Time frame: during the study

Secondary outcomes

  1. Validation of the French version of two self-assessment scales;

    Validate the French-language version of two TSPTc self-assessment scales (SIDES-SR and ITQ) on a French population;

    Time frame: during the study

  2. differences in self-assessment of the participant's overall functioning and personality

    differences in participant's general functioning and personality self-assessment between tCPD and personality disorders - specifically Borderline Personality Disorder (BPD).

    Time frame: during the study

07

Study locations

1 of 1 sites recruiting
  • USAP CHI Robert Ballanger Boulevard Robert Ballanger
    Aulnay-sous-Bois, 93 600, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2021 (actual). Primary completion is estimated for Feb 2023, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2021
First posted
Oct 7, 2021
StartActual
Feb 17, 2021
Primary completionEst.
Feb 2023
CompletionEst.
Feb 2023
Last update
Oct 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05070962
Lead sponsor
Raincy Montfermeil Hospital Group
Responsible party
Sponsor
First posted
Oct 7, 2021
Start date
Feb 17, 2021
Primary completion
Feb 2023 (estimated)
Completion
Feb 2023 (estimated)
Last update
Oct 7, 2021

Study contacts

Marion SIMION
Contact
oriane.simion.etu@univ-lille.fr
+ 33 6 76 25 00 26
Stéphane RUSINEK, Pr
Contact
stephane.rusinek@univ-lille.fr
+33 3 20 41 67 87
Marion SIMION
principal investigator · USAP CHI Robert Ballanger

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion